PYC Therapeutics Limited (PYCXF) Price & Analysis

― Followers

PYCXF Stock Chart & Stats

$1.17

-$0.01(-0.85%)

Jul 24, 2026

―

Day’s Range― - ―

52-Week Range$0.67 - $1.30

Previous CloseN/A

VolumeN/A

Average Volume (3M)N/A

Market Cap

$1.14B

Enterprise Value$723.08M

Total Cash (Recent Filing)$120.69M

Total Debt (Recent Filing)$1.26M

Price to Earnings (P/E)―

Beta0.69

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding983,510,440

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)3.84

Price to Sales (P/S)27.69

P/FCF Ratio-12.39

Enterprise Value/Market Cap0.64

Enterprise Value/Revenue62.03

Enterprise Value/Gross Profit63.68

Enterprise Value/Ebitda-12.09

Forecast

1Y Price Target

$1.98

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageMinimal leverage gives the company financial flexibility to fund ongoing clinical programs and absorb development setbacks without large interest burdens. This durable strength reduces bankruptcy risk and preserves capacity to raise capital on better terms when needed, supporting long-term R&D continuity.

Improving Free Cash Flow EfficiencyAn improving free cash flow profile and FCF-to-net-income >1 indicate better cash conversion and operational efficiency. Over months this can lengthen the clinical runway, reduce near-term financing needs, and demonstrate management's ability to extract cash value despite negative operating results.

Focused RNA Therapeutics PlatformA specialized RNA-based platform targeting genetic diseases represents a durable strategic position with high barriers to entry and significant unmet medical need. Successful clinical advances could yield differentiated assets and partnerships, underpinning long-term value beyond short-term financial cycles.

Bears Say

Declining RevenuesSustained revenue decline and ongoing losses weaken the company's ability to self-fund development and erode investor confidence. Over a multi-month horizon this increases reliance on external capital, risking dilution and potential delays to clinical programs if fundraising conditions deteriorate.

Negative Operating Cash FlowPersistent negative operating cash flow means core operations consume cash rather than generate it, forcing dependency on financing to sustain trials. This structural cash burn constrains strategic optionality and heightens execution risk for multi-stage development programs over the coming months.

Negative Return On Equity And MarginsNegative ROE and margins indicate the company is not converting equity or revenues into returns, reflecting structural unprofitability. This impairs long-term shareholder value creation and suggests current operations and cost structure are inadequate to produce sustainable profitability without material clinical or commercial progress.

PYC Therapeutics Limited News

PYC Therapeutics Gains Safety Clearance to Escalate Dosing in PKD Trial

PYC Therapeutics Limited ( ($AU:PYC) ) has shared an announcement. PYC Therapeutics has received Safety Review Committee clearance...

4d ago

PYC Therapeutics Secures Shareholder Approval at Extraordinary General Meeting

An announcement from PYC Therapeutics Limited ( ($AU:PYC) ) is now available. PYC Therapeutics Limited announced that all...

10d ago

PYC Therapeutics Wins Long-Term U.S. Patents for Lead RNA Drug Candidates

PYC Therapeutics Limited ( ($AU:PYC) ) has issued an announcement. PYC Therapeutics has secured key U.S. composition of...

18d ago

PYC Therapeutics Strengthens Financial Leadership with New CFO Appointment

PYC Therapeutics Limited ( ($AU:PYC) ) has issued an announcement. PYC Therapeutics has appointed Thomas Ulmer as its...

19d ago

PYCXF FAQ

What was PYC Therapeutics Limited’s price range in the past 12 months?

PYC Therapeutics Limited lowest stock price was $0.67 and its highest was $1.30 in the past 12 months.

What is PYC Therapeutics Limited’s market cap?

PYC Therapeutics Limited’s market cap is $1.14B.

When is PYC Therapeutics Limited’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were PYC Therapeutics Limited’s earnings last quarter?

Currently, no data Available

Is PYC Therapeutics Limited overvalued?

According to Wall Street analysts PYC Therapeutics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does PYC Therapeutics Limited pay dividends?

PYC Therapeutics Limited does not currently pay dividends.

What is PYC Therapeutics Limited’s EPS estimate?

PYC Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PYC Therapeutics Limited have?

PYC Therapeutics Limited has 983,510,440 shares outstanding.

What happened to PYC Therapeutics Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of PYC Therapeutics Limited?

Currently, no hedge funds are holding shares in PYCXF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

PYC Therapeutics Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

133.24%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

PYC Therapeutics Limited

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

PYCXF Stock 12 Month Forecast

Average Price Target

$1.98

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.98061032,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.98061032,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.98061032,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.195431563076923,1.260863126153846,1.3262946892307692,1.3917262523076923,1.4571578153846154,1.5225893784615385,1.5880209415384616,1.6534525046153847,1.7188840676923078,1.784315630769231,1.849747193846154,1.915178756923077,{"y":1.98061032,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.195431563076923,1.260863126153846,1.3262946892307692,1.3917262523076923,1.4571578153846154,1.5225893784615385,1.5880209415384616,1.6534525046153847,1.7188840676923078,1.784315630769231,1.849747193846154,1.915178756923077,{"y":1.98061032,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.195431563076923,1.260863126153846,1.3262946892307692,1.3917262523076923,1.4571578153846154,1.5225893784615385,1.5880209415384616,1.6534525046153847,1.7188840676923078,1.784315630769231,1.849747193846154,1.915178756923077,{"y":1.98061032,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.827,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.761,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.816,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.789,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.804,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.971,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.968,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.113,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.954,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Ownership Overview

0.06% Insiders

― Mutual Funds

<0.01% Other Institutional Investors

99.67% Public Companies and

Individual Investors

Detailed Ownership Overview >

Popular Stocks